SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type ...
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis The Afirma XA uses RNA whole-transcriptome sequencing to detect expressed DNA variants and RNA ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO ...
Meta-analysis of independent, real-world studies was presented at ENDO 2022 and shows even better Afirma GSC performance compared to original clinical validation study SOUTH SAN FRANCISCO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback